|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.South Korea |
First Approval Date22 Feb 2024 |
100 Clinical Results associated with Daehan Nupharm Co., Ltd.
0 Patents (Medical) associated with Daehan Nupharm Co., Ltd.
100 Deals associated with Daehan Nupharm Co., Ltd.
100 Translational Medicine associated with Daehan Nupharm Co., Ltd.